Case Report: Exenatide Use During Pregnancy
The DOI matches its Crossref record, with a small difference in title or year; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Objective: To describe the effects on pregnancy outcomes of exposure to exenatide through the first trimester of pregnancy. Methods: A 35-year-old woman with type 2 diabetes mellitus, hypertension, infertility, oligomenorrhea, and morbid obesity, conceived spontaneously while taking multiple medications, including exenatide. The pregnancy was diagnosed incidentally at 14 weeks gestational age, and exenatide was discontinued at that time. Results: Fetal ultrasonography and echocardiography revealed no anomalies, and fetal growth was normal. Preeclampsia became superimposed on chronic hypertension at 38 weeks, and a complicated labor and delivery followed. No congenital anomalies were observed in the infant. Conclusions: In this one case, there were no congenital malformations or other adverse outcomes of pregnancy after exposure to exenatide through the first trimester. This case underscores the importance of counseling all women of reproductive age with preexisting diabetes regarding pregnancy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this case, after an uneventful pregnancy, the patient delivered an anatomically normal fetus despite exposure to exenatide during the period of organogenesis.”
From Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence (2023) · cites this paper as [33]
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Maternal Morbid Obesity and the Risk of Adverse Pregnancy Outcome
Cedergren, M. I. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000107291.46159.00 · Cited by 1,248
Major congenital malformations after first-trimester exposure to ACE inhibitors
Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055202 · Cited by 1,192
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Tang, T., Glanville, J., Hayden, C. J., White, D., Barth, J. H., & Balen, A. H. (2006) · Human Reproduction · doi:10.1093/humrep/dei311 · Cited by 335
Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279
Hoeger, K. M., Kochman, L., Wixom, N., Craig, K., Miller, R. K., & Guzick, D. S. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.104 · Cited by 278
Huber-Buchholz, M.-M. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1470 · Cited by 269
Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat
Stoffers, D. A., Desai, B. M., DeLeon, D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261
Research works printed but not linked: 1
- Huber-Buchholz, 1999, J Clin Endocrinol Metab, 84, 1470
Cited by
Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1215356 · Cited by 174
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review
Drummond, R. F., Seif, K. E., & Reece, E. A. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.08.024 · Cited by 115
Garcia-Flores, V., Romero, R., Miller, D., Xu, Y., Done, B., Veerapaneni, C., Leng, Y., Arenas-Hernandez, M., Khan, N., Panaitescu, B., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01291 · Cited by 71
Zhou, L., Qu, H., Yang, L., & Shou, L. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01500-5 · Cited by 66
Wyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf288 · Cited by 60
Self-citationSafety Considerations with Pharmacological Treatment of Gestational Diabetes Mellitus
Simmons, D. S. (2014) · Drug Safety · doi:10.1007/s40264-014-0253-9 · Cited by 35
GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence
Varughese, M. S., O’Mahony, F., & Varadhan, L. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100298 · Cited by 33
Wyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf116 · Cited by 31
Self-citationPregnancy outcomes following first trimester exposure to semaglutide
Morton, A., & He, J. (2025) · Obstetric Medicine · doi:10.1177/1753495x251346330 · Cited by 22
Özbek, L., Shah, E., Al-Shiab, R., İnal, A., Güldan, M., Afşar, B., Covic, A. C., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70699 · Cited by 22
Effect of GLP1 Agonists on Reproduction
Couldwell, M., Tidwell, A. J., & Taylor, A. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf401 · Cited by 16
Incretin receptor agonism during pregnancy: implications for mother and baby
Dearden, L., & Ozanne, S. E. (2025) · Clinical Science · doi:10.1042/cs20258493 · Cited by 15
Use of dulaglutide in a pregnant woman with type 2 diabetes until third trimester of pregnancy
Molteni, M., Lodigiani, S., Teliti, M., Rotondi, M., & Guazzoni, V. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02331-z · Cited by 13
Hakim, J., Rajesh, D., & Tello, J. A. (2026) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2026.04.037 · Cited by 10
Kettner, J. T., Donnelly, E. T., & Maes, M. L. (2025) · Journal of Pharmacy Practice · doi:10.1177/08971900251376795 · Cited by 10
Exposure to High-Dose Liraglutide in a Pregnant Woman With Obesity
Abushanab, D., Mohammed, H. R., Pallivalapila, A., Thomas, B., Al‐Badriyeh, D., Elkassem, W., Al-Mohannadi, H., Hanssens, Y. I., Khan, S., Mohammed, S., et al. (2025) · O&G Open · doi:10.1097/og9.0000000000000077 · Cited by 9
Lee, I. O., Ghiasi, M., Wong, K. K. Y., & Walker, M. C. (2025) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2025.103191 · Cited by 4
Uysal, N., Horoz, E., Gungor, M., Timarci, I., Sözmen, M. K., Karadas, B., & Kaplan, Y. C. (2026) · Scientific Reports · doi:10.1038/s41598-026-61582-8 · Cited by 4
Maslin, K., Shawe, J., Blowers, S., Ceulemans, M., Hart, K. H., Schoenmakers, S., Rottenstreich, A., Hopper, H., Jensterle, M., Flynn, A. C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70203 · Cited by 3
Teratogenic risks of treated and untreated maternal obesity
Jones, R. E., & Zera, C. (2025) · Seminars in Perinatology · doi:10.1016/j.semperi.2025.152081 · Cited by 2
GLP-1 Receptor Agonists and Fertility: What Is Known So Far?
Becker, A. S., Castilhos, J. P., Shugair, S. A. S., Colombo, T., & Hentschke, M. R. (2026) · JBRA · doi:10.5935/1518-0557.20260028 · Cited by 2
Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies
Fotheringham, P., McGee, R., Chang, R., Kennedy, D. S., & Simmons, D. S. (2026) · Drugs · doi:10.1007/s40265-025-02279-6 · Cited by 1
Perspectives of Obstetricians and Gynaecologists on the Use of Weight Loss Medications
Nolan, C. E., Petch, S., Joyce, N., Glover, L. E., & Crosby, D. A. (2025) · Reproductive Female and Child Health · doi:10.1002/rfc2.70034
Zhou, L., Qu, H., Yang, L., & Shou, L. (2024) · Figshare · doi:10.6084/m9.figshare.26637207
Current awareness: Pharmacoepidemiology and drug safety
(2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1655
Singh, R., Singh, A., & Singh, A. K. (2026) · World Journal of Diabetes · doi:10.4239/wjd.124799
Lau, K., Chopra, A., Mullins, E., Agha-Jaffar, R., Tan, T., Sykes, L., & Yu, C. (2026) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.70339
Diabetes en la mujer embarazada: conceptos fundamentales y tratamiento.
Fresno, J. L. (2021) · Communities in ADDI (Universidad del Pais Vasco)
Metadata
- Authors
- Williams, J., Pomeroy, N. E., Pop-Busui, R., Lash, R., Douyon, L., Chames, M., & Wyckoff, J.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Williams, Jennifer
- Chames, Mark
- Venue
- The Endocrinologist
- Published
- 2009-05
- Volume
- 19
- Issue
- 3
- Pages
- 119-121
- ISSN
- 1051-2144 (ISSN-L)
- OpenAlex
- W1966284758
- Cited by
- 21
- References
- 17
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 3 · 2023: 2 · 2018: 1 · 2014: 1
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Endocrinologist (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- exenatide, type 2 diabetes, pregnancy, first trimester drug exposure, congenital malformations, fetal growth, preeclampsia, maternal obesity, infertility, reproductive counseling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.